Shares of Endologix, Inc. (NASDAQ:ELGX) traded up 5.4% during mid-day trading on Monday . The company traded as high as $0.61 and last traded at $0.59. 520,280 shares changed hands during trading, a decline of 39% from the average session volume of 848,824 shares. The stock had previously closed at $0.56.

ELGX has been the subject of several research reports. Zacks Investment Research cut shares of Endologix from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th. Oppenheimer set a $3.00 price objective on shares of Endologix and gave the company a “hold” rating in a research report on Friday, November 2nd. BTIG Research reissued a “buy” rating on shares of Endologix in a research report on Sunday, November 4th. Finally, ValuEngine upgraded Endologix from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the stock. Endologix has an average rating of “Hold” and a consensus price target of $2.96.

The firm has a market capitalization of $57.93 million, a price-to-earnings ratio of -1.23 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.55 and a debt-to-equity ratio of 4.38.

Large investors have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. purchased a new stake in shares of Endologix in the 4th quarter worth approximately $55,000. Raymond James Financial Services Advisors Inc. lifted its position in shares of Endologix by 408.0% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 99,731 shares of the medical instruments supplier’s stock worth $71,000 after purchasing an additional 80,100 shares during the period. Rhumbline Advisers lifted its position in shares of Endologix by 40.2% in the 4th quarter. Rhumbline Advisers now owns 106,979 shares of the medical instruments supplier’s stock worth $77,000 after purchasing an additional 30,701 shares during the period. Jane Street Group LLC purchased a new stake in Endologix during the third quarter worth $116,000. Finally, SG Americas Securities LLC purchased a new stake in Endologix during the fourth quarter worth $155,000. 74.29% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/endologix-elgx-trading-5-4-higher/2813597.html.

Endologix Company Profile (NASDAQ:ELGX)

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.

Recommended Story: Bull Market

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.